Matterworks is a Somerville, Massachusetts biotech-AI company building foundation models for molecular biology. Its Large Spectral Models (LSMs) are trained on billions of mass spectrometry spectra and read raw molecular signals directly, turning slow, manual mass-spec workflows into automated, untargeted absolute quantitation. Its flagship cloud platform, Pyxis, acts as a predictive omics assistant that converts raw LC-MS data into identified, quantified molecules and biological insight - making mass spectrometry usable by any biologist rather than only specialist analysts.
Jack Geremia is the CEO and co-founder of Matterworks, a Somerville, Massachusetts biotech building Large Spectral Models - foundation models that read raw mass spectrometry signals the way a large language model reads text. A Princeton-trained chemist and former Caltech quantum-control postdoc turned serial biotech founder, he has spent 25-plus years moving technologies from lab bench to market, authoring more than 100 patents and publications. After co-founding Matterworks in 2019 as advising CTO, he stepped into the CEO seat to commercialize Pyxis, the company's generative-AI engine for untargeted molecular annotation, and led the company through a 2025 Series A from Lewis & Clark Partners and OMX Ventures.